- Seres Therapeutics reports new data concerning safety and effectiveness of SER-109 for treating recurrent C.difficile infection.
- This completes Seres package for BLA (Biologics License Application) to the FDA.
- If successful SER-109 would be the first microbic drug to receive BLA approval from the FDA.
- If FDA approval of SER-109 were received, it would surely lead to revaluation of the fortunes of the company and its share price. This is a near term opportunity.
For further details see:
Seres Therapeutics: As Biotech Fades The Case For Seres Investment Strengthens